Skip to main content

ADMA

Stock

ADMA

Stock
Health Care
Biotechnology

Performance overview

ADMA Price
Price Chart

Forward-looking statistics

Beta
1.01
Risk
62.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Company info

SectorHealth Care
IndustryBiotechnology
Employees463
Market cap$2.4B

Fundamentals

Enterprise value$4.4B
Revenue$459.4M
Revenue per employee—
Profit margin45.01%
Debt to equity21.96

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$0.84
Dividend per share—
Revenue per share$1.95
Avg trading volume (30 day)$57M
Avg trading volume (10 day)$70M
Put-call ratio—

Macro factor sensitivity

Growth+1.8
Credit+4.1
Liquidity+0.5
Inflation+1.4
Commodities-2.2
Interest Rates-2.3

Valuation

Dividend yield0.00%
PEG Ratio25.39
Price to sales9.50
P/E Ratio25.39
Enterprise Value to Revenue9.49
Price to book11.68

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day—
Ex. dividend day—

News

Adma Biologics (ADMA) Outperforms Broader Market: What You Need to Know

Adma Biologics (ADMA) concluded the recent trading session at $18.34, signifying a +2.98% move from its prior day's close.

Zacks Investment Research (July 9, 2025)
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?

ADMA's surging Asceniv demand and bold revenue forecasts set it apart in the competitive plasma therapies space.

Zacks Investment Research (June 25, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free